ARS Pharmaceuticals (SPRY) reported Q4 net income Thursday of $0.48 per diluted share.
Three analysts surveyed by FactSet expected a loss of $0.04.
Revenue for the quarter ended Dec. 31 was $86.6 million.
For full-year 2024, the company reported earnings of $0.08 per diluted share, swinging from a loss of $0.57 a year earlier.
Four analysts polled by FactSet expected a loss of $0.52.
Revenue for the year ended Dec. 31 was $89.1 million, up from $30,000 a year earlier.
As of December 31, 2024, the biopharmaceutical company said it had cash, cash equivalents, and short-term investments of $314.0 million, enough to support its operating plans for at least the next three years, the company said.
Shares of the company were up more than 7% in recent premarket activity.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。